| __timestamp | Blueprint Medicines Corporation | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 14097000000 |
| Thursday, January 1, 2015 | 14456000 | 14809000000 |
| Friday, January 1, 2016 | 19218000 | 14837000000 |
| Sunday, January 1, 2017 | 27986000 | 14784000000 |
| Monday, January 1, 2018 | 47928000 | 14455000000 |
| Tuesday, January 1, 2019 | 96388000 | 14350000000 |
| Wednesday, January 1, 2020 | 157743000 | 11615000000 |
| Friday, January 1, 2021 | 195293000 | 12703000000 |
| Saturday, January 1, 2022 | 237374000 | 13677000000 |
| Sunday, January 1, 2023 | 295141000 | 14771000000 |
| Monday, January 1, 2024 | 359272000 | 14730000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Pfizer Inc. and Blueprint Medicines Corporation have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. This consistency reflects Pfizer's established market presence and operational efficiency. In contrast, Blueprint Medicines has shown a dramatic increase in SG&A spending, growing from a modest $7.9 million in 2014 to nearly $295 million in 2023. This 37-fold increase underscores Blueprint's aggressive expansion and investment in market penetration.
These spending patterns highlight the different growth stages and strategic focuses of these two companies, offering a fascinating glimpse into their corporate trajectories.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Pfizer Inc. vs Mesoblast Limited
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends